54
Participants
Start Date
January 15, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
June 30, 2026
VRG50635
"Part 1, no study drug will be administered.~Part 2, the starting dose is 400 mg for 8 weeks (Treatment Period 1) and doses will be escalated to 600 mg for 8 weeks (Treatment Period 2) and 800 mg for 8 weeks (Treatment Period 3).~Part 3, each participant will continue receiving treatment with the highest tolerated dose achieved in Part 2 for up to 40 weeks."
UZ Leuven, Leuven
Stan Cassidy Centre for Rehabilitation (Horizon NB), Montreal
The Neuro - Montréal Neurological Institute-Hospital, Montreal
University of Eastern Finland, Brain Research Unit, Kuopio
Helsinki University Hospital, Helsinki
Turku University Hospital, Turku
University Medical Center Utrecht, Utrecht
Lead Sponsor
Verge Genomics
INDUSTRY